Mingru Zhang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Photodynamic Therapy

Coronavirus Disease

Monoclonal Antibody

Top Venues

Molecular pharmaceutics

Bioconjugate chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Cheng Zhou, Guoquan Li, Zhiyong Quan, Zongke Deng, Guiyu Li, Mingru Zhang, Fei Kang, Weidong Yang, Jing Wang
Prospective Study Comparing [ 99m Tc]Tc-DP-FAPI Quantitative SPECT/CT with [ 68 Ga]Ga-FAPI-04 PET/CT in Patients with Gastrointestinal Tumors. Molecular pharmaceutics (2024)
Tingting Han, Zhiyong Quan, Min Wang, Xiaoli Meng, Mingru Zhang, Jiajun Ye, Guiyu Li, Jing Wang, Fei Kang
Head-to-Head Comparison of 68 Ga-PSMA-11 with 68 Ga-P137 in Patients with Suspected Prostate Cancer. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics 20 (3) (2023)
Jiajun Ye, Weidong Yang, Zhaojuan Xie, Yuhao Yan, Guoquan Li, Guiyu Li, Xiang Li, Wenhui Ma, Fei Kang, Mingru Zhang, Jing Wang
Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131 I-Labeling and SPECT Imaging. Molecular pharmaceutics (2023)
Mingru Zhang, Jiajun Ye, Zhaojuan Xie, Yirong Wang, Wenhui Ma, Fei Kang, Weidong Yang, Jing Wang, Xiaoyuan Shawn Chen
Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers. Molecular pharmaceutics 19 (5) (2022)
Mingru Zhang, Jiajun Ye, Zhaojuan Xie, Yuhao Yan, Jing Wang, Xiaoyuan Shawn Chen
Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands. Bioconjugate chemistry 32 (9) (2021)
Zhe Zhang, Xiaobo Wang, Jiajun Ye, Huanhuan Liu, Jianyang Fang, Mingru Zhang, Yesen Li, Jinxiong Huang, Deliang Zhang, Jing Wang, Xianzhong Zhang
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Molecular pharmaceutics 18 (9) (2021)